Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis
The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool is the cell cycle progression (CCP) score. This systematic review assesses evidence...
Saved in:
| Published in | European urology Vol. 69; no. 1; pp. 107 - 115 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Elsevier B.V
01.01.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool is the cell cycle progression (CCP) score.
This systematic review assesses evidence on the value of the CCP instrument in prostate cancer treatment by reviewing current publications and integrating the results via a meta-analysis.
We performed a review of Medline and Embase in April 2014, according to Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). Unpublished studies were retrieved from the 2013–2014 proceedings of major conferences in the field. Sixteen publications were selected for inclusion.
The results show that use of the CCP score is better than existing assessments at elucidating the aggressive potential of prostate cancer in an individual. The pooled hazard ratio for biochemical recurrence per 1-unit increase in the CCP score was 1.88 in a univariate model and 1.63 in a multivariate model. Four studies showed that CCP testing can impact the decisions of physicians regarding treatment, and potentially lead to a decrease in surgical interventions for low-risk patients.
This review offers a comprehensive overview of existing evidence on CCP testing, and provides clinicians, patients, and policy makers with a strong summary measure of its prognostic validity and clinical utility. It will be important to develop economic studies to measure the impact of such technology on health care systems.
In this paper, we review current evidence related to the cell cycle progression (CCP) score for patients with prostate cancer. We found good evidence suggesting that use of the CCP score improves prognosis, and can be a valuable tool for clinicians in treating patients. The economic benefits are yet to be studied.
This systematic review offers a comprehensive overview of the state of the art of existing evidence on cell cycle progression testing with the Prolaris test, and provides clinicians, patients, and policy-makers with a strong summary value for its prognostic validity. |
|---|---|
| AbstractList | The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool is the cell cycle progression (CCP) score.
This systematic review assesses evidence on the value of the CCP instrument in prostate cancer treatment by reviewing current publications and integrating the results via a meta-analysis.
We performed a review of Medline and Embase in April 2014, according to Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). Unpublished studies were retrieved from the 2013-2014 proceedings of major conferences in the field. Sixteen publications were selected for inclusion.
The results show that use of the CCP score is better than existing assessments at elucidating the aggressive potential of prostate cancer in an individual. The pooled hazard ratio for biochemical recurrence per 1-unit increase in the CCP score was 1.88 in a univariate model and 1.63 in a multivariate model. Four studies showed that CCP testing can impact the decisions of physicians regarding treatment, and potentially lead to a decrease in surgical interventions for low-risk patients.
This review offers a comprehensive overview of existing evidence on CCP testing, and provides clinicians, patients, and policy makers with a strong summary measure of its prognostic validity and clinical utility. It will be important to develop economic studies to measure the impact of such technology on health care systems.
In this paper, we review current evidence related to the cell cycle progression (CCP) score for patients with prostate cancer. We found good evidence suggesting that use of the CCP score improves prognosis, and can be a valuable tool for clinicians in treating patients. The economic benefits are yet to be studied. The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool is the cell cycle progression (CCP) score. This systematic review assesses evidence on the value of the CCP instrument in prostate cancer treatment by reviewing current publications and integrating the results via a meta-analysis. We performed a review of Medline and Embase in April 2014, according to Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). Unpublished studies were retrieved from the 2013–2014 proceedings of major conferences in the field. Sixteen publications were selected for inclusion. The results show that use of the CCP score is better than existing assessments at elucidating the aggressive potential of prostate cancer in an individual. The pooled hazard ratio for biochemical recurrence per 1-unit increase in the CCP score was 1.88 in a univariate model and 1.63 in a multivariate model. Four studies showed that CCP testing can impact the decisions of physicians regarding treatment, and potentially lead to a decrease in surgical interventions for low-risk patients. This review offers a comprehensive overview of existing evidence on CCP testing, and provides clinicians, patients, and policy makers with a strong summary measure of its prognostic validity and clinical utility. It will be important to develop economic studies to measure the impact of such technology on health care systems. In this paper, we review current evidence related to the cell cycle progression (CCP) score for patients with prostate cancer. We found good evidence suggesting that use of the CCP score improves prognosis, and can be a valuable tool for clinicians in treating patients. The economic benefits are yet to be studied. This systematic review offers a comprehensive overview of the state of the art of existing evidence on cell cycle progression testing with the Prolaris test, and provides clinicians, patients, and policy-makers with a strong summary value for its prognostic validity. Abstract Context The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool is the cell cycle progression (CCP) score. Objective This systematic review assesses evidence on the value of the CCP instrument in prostate cancer treatment by reviewing current publications and integrating the results via a meta-analysis. Evidence acquisition We performed a review of Medline and Embase in April 2014, according to Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). Unpublished studies were retrieved from the 2013–2014 proceedings of major conferences in the field. Sixteen publications were selected for inclusion. Evidence synthesis The results show that use of the CCP score is better than existing assessments at elucidating the aggressive potential of prostate cancer in an individual. The pooled hazard ratio for biochemical recurrence per 1-unit increase in the CCP score was 1.88 in a univariate model and 1.63 in a multivariate model. Four studies showed that CCP testing can impact the decisions of physicians regarding treatment, and potentially lead to a decrease in surgical interventions for low-risk patients. Conclusions This review offers a comprehensive overview of existing evidence on CCP testing, and provides clinicians, patients, and policy makers with a strong summary measure of its prognostic validity and clinical utility. It will be important to develop economic studies to measure the impact of such technology on health care systems. Patient summary In this paper, we review current evidence related to the cell cycle progression (CCP) score for patients with prostate cancer. We found good evidence suggesting that use of the CCP score improves prognosis, and can be a valuable tool for clinicians in treating patients. The economic benefits are yet to be studied. The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool is the cell cycle progression (CCP) score.CONTEXTThe process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool is the cell cycle progression (CCP) score.This systematic review assesses evidence on the value of the CCP instrument in prostate cancer treatment by reviewing current publications and integrating the results via a meta-analysis.OBJECTIVEThis systematic review assesses evidence on the value of the CCP instrument in prostate cancer treatment by reviewing current publications and integrating the results via a meta-analysis.We performed a review of Medline and Embase in April 2014, according to Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). Unpublished studies were retrieved from the 2013-2014 proceedings of major conferences in the field. Sixteen publications were selected for inclusion.EVIDENCE ACQUISITIONWe performed a review of Medline and Embase in April 2014, according to Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). Unpublished studies were retrieved from the 2013-2014 proceedings of major conferences in the field. Sixteen publications were selected for inclusion.The results show that use of the CCP score is better than existing assessments at elucidating the aggressive potential of prostate cancer in an individual. The pooled hazard ratio for biochemical recurrence per 1-unit increase in the CCP score was 1.88 in a univariate model and 1.63 in a multivariate model. Four studies showed that CCP testing can impact the decisions of physicians regarding treatment, and potentially lead to a decrease in surgical interventions for low-risk patients.EVIDENCE SYNTHESISThe results show that use of the CCP score is better than existing assessments at elucidating the aggressive potential of prostate cancer in an individual. The pooled hazard ratio for biochemical recurrence per 1-unit increase in the CCP score was 1.88 in a univariate model and 1.63 in a multivariate model. Four studies showed that CCP testing can impact the decisions of physicians regarding treatment, and potentially lead to a decrease in surgical interventions for low-risk patients.This review offers a comprehensive overview of existing evidence on CCP testing, and provides clinicians, patients, and policy makers with a strong summary measure of its prognostic validity and clinical utility. It will be important to develop economic studies to measure the impact of such technology on health care systems.CONCLUSIONSThis review offers a comprehensive overview of existing evidence on CCP testing, and provides clinicians, patients, and policy makers with a strong summary measure of its prognostic validity and clinical utility. It will be important to develop economic studies to measure the impact of such technology on health care systems.In this paper, we review current evidence related to the cell cycle progression (CCP) score for patients with prostate cancer. We found good evidence suggesting that use of the CCP score improves prognosis, and can be a valuable tool for clinicians in treating patients. The economic benefits are yet to be studied.PATIENT SUMMARYIn this paper, we review current evidence related to the cell cycle progression (CCP) score for patients with prostate cancer. We found good evidence suggesting that use of the CCP score improves prognosis, and can be a valuable tool for clinicians in treating patients. The economic benefits are yet to be studied. |
| Author | Sommariva, Silvia Tarricone, Rosanna Montorsi, Francesco Lazzeri, Massimo Ricciardi, Walter |
| Author_xml | – sequence: 1 givenname: Silvia surname: Sommariva fullname: Sommariva, Silvia email: silvia.sommariva@unibocconi.it organization: Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy – sequence: 2 givenname: Rosanna surname: Tarricone fullname: Tarricone, Rosanna organization: Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy – sequence: 3 givenname: Massimo surname: Lazzeri fullname: Lazzeri, Massimo organization: Division of Oncology, Unit of Urology, Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy – sequence: 4 givenname: Walter surname: Ricciardi fullname: Ricciardi, Walter organization: Department of Public Health, Catholic University of the Sacred Heart, Rome, Italy – sequence: 5 givenname: Francesco surname: Montorsi fullname: Montorsi, Francesco organization: Division of Oncology, Unit of Urology, Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25481455$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkl1rFDEYhYNU7Lb6D0Ry6c2Mb5L5yBQRyuIXVCyuehuymXds1tmkTTKWAX-8Gba9EaR4lZtznnDOeU_IkfMOCXnOoGTAmle7EqcwBV9yYFXJWAlCPiIrJltRtHUDR2QFAnjBpZDH5CTGHQCIuhNPyDGvK8mqul6R35fB_3A-Jmvodz1OSP1A0xXSNY4jXc9mRLpIAsZovaMb4wNS6-ilThZdivTWpqtFEpNO2aadwXBGz-lmjgn3egF_wV8Wb6l2Pf2ESRfa6XGONj4ljwc9Rnx2956Sb-_efl1_KC4-v_-4Pr8oTA0iFRoaAYiD6HFggLLiHHTbta2BHqCWUnfddmhMZaRA1H2Dctu1vKtE14teduKUvDxwr4O_mTAmtbfR5IDaoZ-iYm3Nug7qhmXpizvptN1jr66D3eswq_vGsuDsIDA5cgw4KGNz8txNCtqOioFa5lE7dZhHLfMoxlSeJ5urv8z3_Adsbw42zCXlKoOKJpdvsLcBTVK9t_8LMKN11ujxJ84Yd34KeZJchIpcgdosh7PcDauAcc6qDHj9b8DD__8B_TLV3Q |
| CitedBy_id | crossref_primary_10_1002_pros_24103 crossref_primary_10_1111_bju_13911 crossref_primary_10_1016_j_biopha_2016_01_004 crossref_primary_10_1016_j_lfs_2021_120264 crossref_primary_10_2217_fon_2018_0287 crossref_primary_10_1158_0008_5472_CAN_17_1924 crossref_primary_10_1016_j_ajur_2024_09_009 crossref_primary_10_3390_cancers16020316 crossref_primary_10_3389_fonc_2021_695006 crossref_primary_10_3389_fonc_2021_625452 crossref_primary_10_3390_ijms241512508 crossref_primary_10_3390_diagnostics8030062 crossref_primary_10_3390_cancers12123790 crossref_primary_10_1016_j_ucl_2020_10_005 crossref_primary_10_1016_j_urolonc_2016_04_017 crossref_primary_10_1080_14737159_2020_1816827 crossref_primary_10_1177_03000605211016624 crossref_primary_10_1016_j_euo_2023_06_002 crossref_primary_10_1111_pin_12398 crossref_primary_10_1002_cam4_70641 crossref_primary_10_1371_journal_pone_0178316 crossref_primary_10_3390_cancers14153765 crossref_primary_10_1002_ctm2_138 crossref_primary_10_1038_modpathol_2017_168 crossref_primary_10_3390_ijms22189926 crossref_primary_10_1007_s00432_019_03089_6 crossref_primary_10_1038_bjc_2015_223 crossref_primary_10_1186_s12894_023_01275_w crossref_primary_10_2217_pme_2019_0084 crossref_primary_10_1080_23808993_2017_1372687 crossref_primary_10_1016_j_urology_2016_11_038 crossref_primary_10_1038_s41598_021_98489_5 crossref_primary_10_3390_jcm11237164 crossref_primary_10_2196_45493 crossref_primary_10_1002_cnr2_1535 crossref_primary_10_1016_j_clgc_2021_01_003 crossref_primary_10_1200_JCO_24_00608 crossref_primary_10_1038_s41391_020_00305_0 crossref_primary_10_32074_1591_951X_822 crossref_primary_10_3390_cancers12051146 crossref_primary_10_1002_cpt_2582 crossref_primary_10_1016_j_heliyon_2022_e10081 crossref_primary_10_1016_j_ajur_2022_05_004 crossref_primary_10_1016_j_humpath_2017_06_007 crossref_primary_10_1002_cncr_29496 crossref_primary_10_3390_curroncol30020129 crossref_primary_10_3389_fonc_2021_676716 crossref_primary_10_1007_s12094_015_1431_7 crossref_primary_10_1002_cncr_32821 crossref_primary_10_1371_journal_pone_0232395 crossref_primary_10_1371_journal_pone_0173600 crossref_primary_10_1016_j_biotechadv_2016_11_009 crossref_primary_10_1038_s41391_024_00888_y crossref_primary_10_3390_jpm12010065 crossref_primary_10_3390_diagnostics13213350 |
| Cites_doi | 10.1200/JCO.2012.46.4396 10.1001/jama.2009.1348 10.1016/S1470-2045(13)70442-X 10.1016/j.juro.2014.02.003 10.1016/S0022-5347(01)64856-0 10.1136/bmj.c221 10.1016/S0022-5347(05)68578-3 10.1200/jco.2013.31.15_suppl.5005 10.1038/ncponc0287 10.1056/NEJMoa021967 10.1016/j.ijrobp.2013.06.322 10.1016/j.juro.2013.02.2940 10.1093/annonc/mdl270 10.1038/bjc.2012.39 10.1016/j.juro.2007.05.039 10.1200/jco.2014.32.4_suppl.13 10.1197/jamia.M1752 10.1111/j.1442-2042.2012.03175.x 10.1002/pros.21159 10.1016/j.ijrobp.2013.04.043 10.1016/j.juro.2014.02.2520 10.1073/pnas.0409462102 10.1046/j.1365-2559.1999.00862.x 10.1111/j.1464-410X.2011.10365.x 10.1200/jco.2013.31.6_suppl.127 10.1185/03007995.2013.873398 10.1200/jco.2013.31.15_suppl.5043 10.1056/NEJMoa1113162 10.7326/0003-4819-151-4-200908180-00135 10.1016/S1470-2045(10)70295-3 10.1016/j.eururo.2013.07.001 10.1200/jco.2014.32.4_suppl.47 10.1038/sj.bjc.6604924 10.1200/jco.2013.31.6_suppl.67 10.1159/000283013 10.1016/S0140-6736(05)70933-8 10.1136/bmj.b4817 10.1016/j.juro.2010.02.013 |
| ContentType | Journal Article |
| Copyright | 2014 European Association of Urology European Association of Urology Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2014 European Association of Urology – notice: European Association of Urology – notice: Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.eururo.2014.11.038 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-7560 |
| EndPage | 115 |
| ExternalDocumentID | 25481455 10_1016_j_eururo_2014_11_038 S0302283814012214 1_s2_0_S0302283814012214 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 0~B 1B1 1P~ 1~. 1~5 29G 30W 34G 39C 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 8UI AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYIC AAYWO ABBQC ABBTS ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWCG ABWVN ABXDB ACDAQ ACIEU ACQXL ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AEYAO AFJKZ AFPUW AFRHN AFSIO AFTJW AFXIZ AGCQF AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CAG COF CS3 CYUIP DU5 E0A EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FB. FDB FEDTE FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O1H O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 RKO ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UDS UJ6 UV1 X7M Z5R ZGI ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU AZPMC EFLBG LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c503t-a0630eef3def10e84220a7977c0d00588a99bf6c4c83eead6e8b9729439d3d893 |
| IEDL.DBID | .~1 |
| ISSN | 0302-2838 1873-7560 |
| IngestDate | Tue Aug 05 11:27:37 EDT 2025 Mon Jul 21 05:32:04 EDT 2025 Thu Apr 24 23:03:50 EDT 2025 Tue Jul 01 02:35:25 EDT 2025 Fri Feb 23 02:16:42 EST 2024 Sun Feb 23 10:19:56 EST 2025 Tue Aug 26 16:34:23 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cell cycle progression score Prognostic value Prostate cancer |
| Language | English |
| License | Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c503t-a0630eef3def10e84220a7977c0d00588a99bf6c4c83eead6e8b9729439d3d893 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| PMID | 25481455 |
| PQID | 1751990561 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1751990561 pubmed_primary_25481455 crossref_citationtrail_10_1016_j_eururo_2014_11_038 crossref_primary_10_1016_j_eururo_2014_11_038 elsevier_sciencedirect_doi_10_1016_j_eururo_2014_11_038 elsevier_clinicalkeyesjournals_1_s2_0_S0302283814012214 elsevier_clinicalkey_doi_10_1016_j_eururo_2014_11_038 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-01-01 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | European urology |
| PublicationTitleAlternate | Eur Urol |
| PublicationYear | 2016 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Luengo-Fernandez, Leal, Gray, Sullivan (bib0220) 2013; 14 Dillioglugil, Leibman, Leibman, Kattan, Rosas, Scardino (bib0040) 1997; 157 Cuzick, Berney, Fisher (bib0150) 2012; 106 Cuzick, Stone, Fisher (bib0195) 2014; 191 Riley, Lambert, Abo-Zaid (bib0245) 2010; 340 Heinzer, Graefen, Noldus, Hammerer, Huland (bib0045) 1997; 59 Shore, Concepcion, Saltzstein (bib0145) 2013; 30 Wang, Klijn, Zhang (bib0075) 2005; 365 Moher, Liberati, Tetzlaff, Altman (bib0100) 2009; 151 Chen (bib0025) 2013; 64 Altman, Riley (bib0115) 2005; 2 Cooperberg, Simko, Cowan (bib0135) 2013; 31 Wilt, Brawer, Jones (bib0035) 2012; 367 Huang, Sadetsky, Penson (bib0060) 2010; 183 Latini, Hart, Knight (bib0030) 2007; 178 Catalona, Carvalhal, Mager, Smith (bib0055) 1999; 162 Brawer, Cuzick, Cooperberg (bib0190) 2013; 31 Salama, Freedland, Gerber (bib0215) 2013; 87 Loddo, Kingsbury, Rashid (bib0090) 2009; 100 Hall, Going (bib0110) 1999; 35 Freedland, Gerber, Reid (bib0155) 2013; 86 Carvalho, Welbourn, Reid (bib0205) 2013; 189 Sotiriou, Desmedt (bib0085) 2006; 17 Schlomm, Sangale, Lanchbury (bib0185) 2013; 31 Sousa, Ribeiro (bib0120) 2009; 92 Cuzick, Swanson, Fisher (bib0140) 2011; 12 Roehrborn, Black (bib0225) 2011; 108 Lu-Yao, Albertsen, Moore (bib0020) 2009; 302 Capitanio, Briganti, Gallina (bib0235) 2010; 70 Health at a glance 2011: OECD data. Mortality from cancer. Rector, Taylor, Wilt (bib0125) 2012 Centers for Disease Control and Prevention. ACCE model process for evaluating genetic tests. January 3, 2010. Wilczynski, Haynes (bib0105) 2005; 12 Miyake, Fujisawa (bib0230) 2013; 20 Smith, King, Egger (bib0065) 2009; 339 Drummond, Schulpher, Torrance (bib0130) 2005 Brawer, Cooperberg, Freedland (bib0210) 2013; 31 Bishoff, Freedland, Gerber (bib0160) 2014; 192 Crawford, Scholz, Kar (bib0165) 2014; 30 Cooperberg, Freedland, Schlomm (bib0200) 2014; 32 Istituto Toscano Tumori. Carcinoma della prostata: raccomandazioni cliniche. Crawford, Shore, Scardino (bib0175) 2014; 32 Associazione Italiana di Oncologia Medica. Linee guida carcinoma della prostata AIOM 2013. Davidson, van den Ouden, Schroeder (bib0050) 1996; 29 US Cancer Statistics Working Group. United States cancer statistics: 1999–2010 incidence and mortality web-based report. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013. van de Vijver, He, van’t Veer (bib0070) 2002; 347 Shore, Abbott, Concepcion (bib0180) 2013; 31 Chang, Nuyten, Sneddon (bib0080) 2005; 102 Kern, Partin (bib0095) 2013; 15 Chang (10.1016/j.eururo.2014.11.038_bib0080) 2005; 102 Roehrborn (10.1016/j.eururo.2014.11.038_bib0225) 2011; 108 Miyake (10.1016/j.eururo.2014.11.038_bib0230) 2013; 20 van de Vijver (10.1016/j.eururo.2014.11.038_bib0070) 2002; 347 Wang (10.1016/j.eururo.2014.11.038_bib0075) 2005; 365 Wilt (10.1016/j.eururo.2014.11.038_bib0035) 2012; 367 Brawer (10.1016/j.eururo.2014.11.038_bib0210) 2013; 31 Cuzick (10.1016/j.eururo.2014.11.038_bib0195) 2014; 191 Catalona (10.1016/j.eururo.2014.11.038_bib0055) 1999; 162 Hall (10.1016/j.eururo.2014.11.038_bib0110) 1999; 35 Davidson (10.1016/j.eururo.2014.11.038_bib0050) 1996; 29 Kern (10.1016/j.eururo.2014.11.038_bib0095) 2013; 15 Heinzer (10.1016/j.eururo.2014.11.038_bib0045) 1997; 59 Cooperberg (10.1016/j.eururo.2014.11.038_bib0135) 2013; 31 Rector (10.1016/j.eururo.2014.11.038_bib0125) 2012 Shore (10.1016/j.eururo.2014.11.038_bib0180) 2013; 31 Capitanio (10.1016/j.eururo.2014.11.038_bib0235) 2010; 70 Chen (10.1016/j.eururo.2014.11.038_bib0025) 2013; 64 Crawford (10.1016/j.eururo.2014.11.038_bib0175) 2014; 32 Freedland (10.1016/j.eururo.2014.11.038_bib0155) 2013; 86 Moher (10.1016/j.eururo.2014.11.038_bib0100) 2009; 151 Huang (10.1016/j.eururo.2014.11.038_bib0060) 2010; 183 Smith (10.1016/j.eururo.2014.11.038_bib0065) 2009; 339 Schlomm (10.1016/j.eururo.2014.11.038_bib0185) 2013; 31 Altman (10.1016/j.eururo.2014.11.038_bib0115) 2005; 2 Carvalho (10.1016/j.eururo.2014.11.038_bib0205) 2013; 189 Drummond (10.1016/j.eururo.2014.11.038_bib0130) 2005 Crawford (10.1016/j.eururo.2014.11.038_bib0165) 2014; 30 10.1016/j.eururo.2014.11.038_bib0170 Shore (10.1016/j.eururo.2014.11.038_bib0145) 2013; 30 Bishoff (10.1016/j.eururo.2014.11.038_bib0160) 2014; 192 Riley (10.1016/j.eururo.2014.11.038_bib0245) 2010; 340 Latini (10.1016/j.eururo.2014.11.038_bib0030) 2007; 178 Sotiriou (10.1016/j.eururo.2014.11.038_bib0085) 2006; 17 Salama (10.1016/j.eururo.2014.11.038_bib0215) 2013; 87 Brawer (10.1016/j.eururo.2014.11.038_bib0190) 2013; 31 10.1016/j.eururo.2014.11.038_bib0010 Cooperberg (10.1016/j.eururo.2014.11.038_bib0200) 2014; 32 10.1016/j.eururo.2014.11.038_bib0015 Sousa (10.1016/j.eururo.2014.11.038_bib0120) 2009; 92 Wilczynski (10.1016/j.eururo.2014.11.038_bib0105) 2005; 12 Cuzick (10.1016/j.eururo.2014.11.038_bib0140) 2011; 12 Loddo (10.1016/j.eururo.2014.11.038_bib0090) 2009; 100 Lu-Yao (10.1016/j.eururo.2014.11.038_bib0020) 2009; 302 Cuzick (10.1016/j.eururo.2014.11.038_bib0150) 2012; 106 Dillioglugil (10.1016/j.eururo.2014.11.038_bib0040) 1997; 157 Luengo-Fernandez (10.1016/j.eururo.2014.11.038_bib0220) 2013; 14 10.1016/j.eururo.2014.11.038_bib0005 10.1016/j.eururo.2014.11.038_bib0240 |
| References_xml | – volume: 31 start-page: 1428 year: 2013 end-page: 1434 ident: bib0135 article-title: Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort publication-title: J Clin Oncol – volume: 70 start-page: 1371 year: 2010 end-page: 1378 ident: bib0235 article-title: Predictive models before and after radical prostatectomy publication-title: Prostate – volume: 183 start-page: 2206 year: 2010 end-page: 2212 ident: bib0060 article-title: Health related quality of life for men treated for localized prostate cancer with long-term followup publication-title: J Urol – volume: 347 start-page: 1999 year: 2002 end-page: 2009 ident: bib0070 article-title: A gene-expression signature as a predictor of survival in breast cancer publication-title: N Engl J Med – volume: 32 start-page: 47 year: 2014 ident: bib0175 article-title: CCP score and risk stratification for prostate cancer patients at biopsy publication-title: J Clin Oncol – volume: 31 start-page: 67 year: 2013 ident: bib0210 article-title: Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort publication-title: J Clin Oncol – volume: 86 start-page: 848 year: 2013 end-page: 853 ident: bib0155 article-title: Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy publication-title: Int J Radiat Oncol Biol Phys – volume: 32 start-page: 13 year: 2014 ident: bib0200 article-title: Predicting radical prostatectomy outcome: cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7 publication-title: J Clin Oncol – volume: 14 start-page: 1165 year: 2013 end-page: 1174 ident: bib0220 article-title: Economic burden of cancer across the European Union: a population based cost analysis publication-title: Lancet Oncol – volume: 340 start-page: c221 year: 2010 ident: bib0245 article-title: Meta-analysis of individual participant data: rationale, conduct, and reporting publication-title: BMJ – volume: 30 start-page: 547 year: 2013 end-page: 553 ident: bib0145 article-title: Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer publication-title: Curr Med Res Opin – volume: 12 start-page: 245 year: 2011 end-page: 255 ident: bib0140 article-title: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study publication-title: Lancet Oncol – volume: 17 start-page: 259 year: 2006 end-page: 262 ident: bib0085 article-title: Gene expression profiling in breast cancer publication-title: Ann Oncol – volume: 191 start-page: e936 year: 2014 ident: bib0195 article-title: Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort publication-title: J Urol – volume: 59 start-page: 30 year: 1997 end-page: 33 ident: bib0045 article-title: Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience publication-title: Urol Int – volume: 20 start-page: 301 year: 2013 end-page: 311 ident: bib0230 article-title: Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches publication-title: Int J Urol – reference: Centers for Disease Control and Prevention. ACCE model process for evaluating genetic tests. January 3, 2010. – volume: 106 start-page: 1095 year: 2012 end-page: 1099 ident: bib0150 article-title: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort publication-title: Br J Cancer – volume: 35 start-page: 489 year: 1999 end-page: 494 ident: bib0110 article-title: Predicting the future: a critical appraisal of cancer prognosis studies publication-title: Histopathology – reference: Health at a glance 2011: OECD data. Mortality from cancer. – volume: 100 start-page: 959 year: 2009 end-page: 970 ident: bib0090 article-title: Cell-cycle phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer publication-title: Br J Cancer – volume: 102 start-page: 3738 year: 2005 end-page: 3743 ident: bib0080 article-title: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival publication-title: Proc Natl Acad Sci U S A – volume: 29 start-page: 168 year: 1996 end-page: 173 ident: bib0050 article-title: Radical prostatectomy: prospective assessment of mortality and morbidity publication-title: Eur Urol – volume: 31 start-page: 5005 year: 2013 ident: bib0190 article-title: Prolaris: a novel genetic test for prostate cancer prognosis publication-title: J Clin Oncol – year: 2012 ident: bib0125 article-title: Systematic review of prognostic tests. Methods guide – Chapter 12. Department of Health and Human Services publication-title: Agency for Healthcare Research and Quality; – volume: 2 start-page: 466 year: 2005 end-page: 472 ident: bib0115 article-title: Primer: an evidence-based approach to prognostic markers publication-title: Nat Clin Pract Oncol – volume: 367 start-page: 203 year: 2012 end-page: 213 ident: bib0035 article-title: Radical prostatectomy versus observation for localized prostate cancer publication-title: N Engl J Med – volume: 31 start-page: 5043 year: 2013 ident: bib0185 article-title: Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology publication-title: J Clin Oncol – year: 2005 ident: bib0130 article-title: Methods for the economic evaluation of health care programmes – volume: 365 start-page: 671 year: 2005 end-page: 679 ident: bib0075 article-title: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer publication-title: Lancet – volume: 162 start-page: 433 year: 1999 end-page: 438 ident: bib0055 article-title: Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies publication-title: J Urol – volume: 192 start-page: 409 year: 2014 end-page: 414 ident: bib0160 article-title: Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy publication-title: J Urol – volume: 15 start-page: 208 year: 2013 end-page: 209 ident: bib0095 article-title: Genetic tests for prostate cancer publication-title: Rev Urol – volume: 108 start-page: 806 year: 2011 end-page: 813 ident: bib0225 article-title: The economic burden of prostate cancer publication-title: BJU Intl – volume: 302 start-page: 1202 year: 2009 end-page: 1209 ident: bib0020 article-title: Outcomes of localized prostate cancer following conservative management publication-title: JAMA – volume: 178 start-page: 826 year: 2007 end-page: 831 ident: bib0030 article-title: The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance publication-title: J Urol – reference: Istituto Toscano Tumori. Carcinoma della prostata: raccomandazioni cliniche. – volume: 31 start-page: 127 year: 2013 ident: bib0180 article-title: Stratification of risk for patients with prostate cancer at biopsy using CCP score publication-title: J Clin Oncol – volume: 64 start-page: 916 year: 2013 end-page: 918 ident: bib0025 article-title: Making individualized decisions in the midst of uncertainties: the case of prostate cancer and biochemical recurrence publication-title: Eur Urol – volume: 339 start-page: b4817 year: 2009 ident: bib0065 article-title: Quality of life three years after diagnosis of localised prostate cancer: population based cohort study publication-title: BMJ – reference: US Cancer Statistics Working Group. United States cancer statistics: 1999–2010 incidence and mortality web-based report. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013. – volume: 157 start-page: 1760 year: 1997 end-page: 1767 ident: bib0040 article-title: Risk factors for complications and morbidity after radical retropubic prostatectomy publication-title: J Urol – volume: 87 start-page: 125 year: 2013 ident: bib0215 article-title: Cell cycle progression (CCP) score significantly predicts PSA failure after EBRT publication-title: Int J Radiat Oncol Biol Phys – volume: 30 start-page: 1025 year: 2014 end-page: 1031 ident: bib0165 article-title: Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry publication-title: J Clin Oncol – volume: 151 start-page: 264 year: 2009 end-page: 269 ident: bib0100 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: Ann Intern Med – volume: 92 start-page: 229 year: 2009 end-page: 238 ident: bib0120 article-title: Systematic review and meta-analysis of diagnostic and prognostic studies publication-title: Arq Bras Cardiol – volume: 189 start-page: e605 year: 2013 ident: bib0205 article-title: Evidence for a cell cycle proliferation “field effect” in prostate cancer publication-title: J Urol – reference: Associazione Italiana di Oncologia Medica. Linee guida carcinoma della prostata AIOM 2013. – volume: 12 start-page: 481 year: 2005 end-page: 485 ident: bib0105 article-title: Optimal search strategies for detecting clinically sound prognostic studies in EMBASE: an analytic survey publication-title: J Am Med Inform Assoc – volume: 31 start-page: 1428 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0135 article-title: Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort publication-title: J Clin Oncol doi: 10.1200/JCO.2012.46.4396 – ident: 10.1016/j.eururo.2014.11.038_bib0240 – volume: 302 start-page: 1202 year: 2009 ident: 10.1016/j.eururo.2014.11.038_bib0020 article-title: Outcomes of localized prostate cancer following conservative management publication-title: JAMA doi: 10.1001/jama.2009.1348 – volume: 14 start-page: 1165 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0220 article-title: Economic burden of cancer across the European Union: a population based cost analysis publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70442-X – volume: 92 start-page: 229 year: 2009 ident: 10.1016/j.eururo.2014.11.038_bib0120 article-title: Systematic review and meta-analysis of diagnostic and prognostic studies publication-title: Arq Bras Cardiol – ident: 10.1016/j.eururo.2014.11.038_bib0170 – volume: 192 start-page: 409 year: 2014 ident: 10.1016/j.eururo.2014.11.038_bib0160 article-title: Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy publication-title: J Urol doi: 10.1016/j.juro.2014.02.003 – volume: 157 start-page: 1760 year: 1997 ident: 10.1016/j.eururo.2014.11.038_bib0040 article-title: Risk factors for complications and morbidity after radical retropubic prostatectomy publication-title: J Urol doi: 10.1016/S0022-5347(01)64856-0 – volume: 340 start-page: c221 year: 2010 ident: 10.1016/j.eururo.2014.11.038_bib0245 article-title: Meta-analysis of individual participant data: rationale, conduct, and reporting publication-title: BMJ doi: 10.1136/bmj.c221 – volume: 162 start-page: 433 year: 1999 ident: 10.1016/j.eururo.2014.11.038_bib0055 article-title: Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies publication-title: J Urol doi: 10.1016/S0022-5347(05)68578-3 – volume: 31 start-page: 5005 issue: Suppl 15 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0190 article-title: Prolaris: a novel genetic test for prostate cancer prognosis publication-title: J Clin Oncol doi: 10.1200/jco.2013.31.15_suppl.5005 – volume: 2 start-page: 466 year: 2005 ident: 10.1016/j.eururo.2014.11.038_bib0115 article-title: Primer: an evidence-based approach to prognostic markers publication-title: Nat Clin Pract Oncol doi: 10.1038/ncponc0287 – volume: 347 start-page: 1999 year: 2002 ident: 10.1016/j.eururo.2014.11.038_bib0070 article-title: A gene-expression signature as a predictor of survival in breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa021967 – volume: 15 start-page: 208 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0095 article-title: Genetic tests for prostate cancer publication-title: Rev Urol – volume: 87 start-page: 125 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0215 article-title: Cell cycle progression (CCP) score significantly predicts PSA failure after EBRT publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2013.06.322 – volume: 189 start-page: e605 issue: Suppl 4 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0205 article-title: Evidence for a cell cycle proliferation “field effect” in prostate cancer publication-title: J Urol doi: 10.1016/j.juro.2013.02.2940 – volume: 17 start-page: 259 issue: Suppl 10 year: 2006 ident: 10.1016/j.eururo.2014.11.038_bib0085 article-title: Gene expression profiling in breast cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdl270 – volume: 106 start-page: 1095 year: 2012 ident: 10.1016/j.eururo.2014.11.038_bib0150 article-title: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort publication-title: Br J Cancer doi: 10.1038/bjc.2012.39 – volume: 178 start-page: 826 year: 2007 ident: 10.1016/j.eururo.2014.11.038_bib0030 article-title: The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance publication-title: J Urol doi: 10.1016/j.juro.2007.05.039 – volume: 32 start-page: 13 issue: Suppl 4 year: 2014 ident: 10.1016/j.eururo.2014.11.038_bib0200 article-title: Predicting radical prostatectomy outcome: cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7 publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.4_suppl.13 – volume: 12 start-page: 481 year: 2005 ident: 10.1016/j.eururo.2014.11.038_bib0105 article-title: Optimal search strategies for detecting clinically sound prognostic studies in EMBASE: an analytic survey publication-title: J Am Med Inform Assoc doi: 10.1197/jamia.M1752 – volume: 20 start-page: 301 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0230 article-title: Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches publication-title: Int J Urol doi: 10.1111/j.1442-2042.2012.03175.x – volume: 70 start-page: 1371 year: 2010 ident: 10.1016/j.eururo.2014.11.038_bib0235 article-title: Predictive models before and after radical prostatectomy publication-title: Prostate doi: 10.1002/pros.21159 – volume: 86 start-page: 848 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0155 article-title: Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2013.04.043 – ident: 10.1016/j.eururo.2014.11.038_bib0015 – volume: 191 start-page: e936 issue: 4 Suppl year: 2014 ident: 10.1016/j.eururo.2014.11.038_bib0195 article-title: Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort publication-title: J Urol doi: 10.1016/j.juro.2014.02.2520 – volume: 29 start-page: 168 year: 1996 ident: 10.1016/j.eururo.2014.11.038_bib0050 article-title: Radical prostatectomy: prospective assessment of mortality and morbidity publication-title: Eur Urol – ident: 10.1016/j.eururo.2014.11.038_bib0005 – volume: 102 start-page: 3738 year: 2005 ident: 10.1016/j.eururo.2014.11.038_bib0080 article-title: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0409462102 – volume: 35 start-page: 489 year: 1999 ident: 10.1016/j.eururo.2014.11.038_bib0110 article-title: Predicting the future: a critical appraisal of cancer prognosis studies publication-title: Histopathology doi: 10.1046/j.1365-2559.1999.00862.x – volume: 108 start-page: 806 year: 2011 ident: 10.1016/j.eururo.2014.11.038_bib0225 article-title: The economic burden of prostate cancer publication-title: BJU Intl doi: 10.1111/j.1464-410X.2011.10365.x – volume: 31 start-page: 127 issue: Suppl 6 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0180 article-title: Stratification of risk for patients with prostate cancer at biopsy using CCP score publication-title: J Clin Oncol doi: 10.1200/jco.2013.31.6_suppl.127 – ident: 10.1016/j.eururo.2014.11.038_bib0010 – volume: 30 start-page: 547 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0145 article-title: Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer publication-title: Curr Med Res Opin doi: 10.1185/03007995.2013.873398 – volume: 31 start-page: 5043 issue: Suppl 15 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0185 article-title: Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology publication-title: J Clin Oncol doi: 10.1200/jco.2013.31.15_suppl.5043 – volume: 367 start-page: 203 year: 2012 ident: 10.1016/j.eururo.2014.11.038_bib0035 article-title: Radical prostatectomy versus observation for localized prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1113162 – volume: 151 start-page: 264 year: 2009 ident: 10.1016/j.eururo.2014.11.038_bib0100 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: Ann Intern Med doi: 10.7326/0003-4819-151-4-200908180-00135 – volume: 12 start-page: 245 year: 2011 ident: 10.1016/j.eururo.2014.11.038_bib0140 article-title: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70295-3 – volume: 30 start-page: 1025 year: 2014 ident: 10.1016/j.eururo.2014.11.038_bib0165 article-title: Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry publication-title: J Clin Oncol – volume: 64 start-page: 916 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0025 article-title: Making individualized decisions in the midst of uncertainties: the case of prostate cancer and biochemical recurrence publication-title: Eur Urol doi: 10.1016/j.eururo.2013.07.001 – volume: 32 start-page: 47 issue: Suppl 4 year: 2014 ident: 10.1016/j.eururo.2014.11.038_bib0175 article-title: CCP score and risk stratification for prostate cancer patients at biopsy publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.4_suppl.47 – volume: 100 start-page: 959 year: 2009 ident: 10.1016/j.eururo.2014.11.038_bib0090 article-title: Cell-cycle phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604924 – volume: 31 start-page: 67 issue: Suppl 6 year: 2013 ident: 10.1016/j.eururo.2014.11.038_bib0210 article-title: Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort publication-title: J Clin Oncol doi: 10.1200/jco.2013.31.6_suppl.67 – volume: 59 start-page: 30 year: 1997 ident: 10.1016/j.eururo.2014.11.038_bib0045 article-title: Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience publication-title: Urol Int doi: 10.1159/000283013 – volume: 365 start-page: 671 year: 2005 ident: 10.1016/j.eururo.2014.11.038_bib0075 article-title: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer publication-title: Lancet doi: 10.1016/S0140-6736(05)70933-8 – year: 2012 ident: 10.1016/j.eururo.2014.11.038_bib0125 article-title: Systematic review of prognostic tests. Methods guide – Chapter 12. Department of Health and Human Services publication-title: Agency for Healthcare Research and Quality; – volume: 339 start-page: b4817 year: 2009 ident: 10.1016/j.eururo.2014.11.038_bib0065 article-title: Quality of life three years after diagnosis of localised prostate cancer: population based cohort study publication-title: BMJ doi: 10.1136/bmj.b4817 – year: 2005 ident: 10.1016/j.eururo.2014.11.038_bib0130 – volume: 183 start-page: 2206 year: 2010 ident: 10.1016/j.eururo.2014.11.038_bib0060 article-title: Health related quality of life for men treated for localized prostate cancer with long-term followup publication-title: J Urol doi: 10.1016/j.juro.2010.02.013 |
| SSID | ssj0003593 |
| Score | 2.4373693 |
| SecondaryResourceType | review_article |
| Snippet | The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit... Abstract Context The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could,... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 107 |
| SubjectTerms | Cell Cycle - genetics Cell Cycle - physiology Cell cycle progression score Genes, cdc Humans Male Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Predictive Value of Tests Prognosis Prognostic value Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - genetics Prostatic Neoplasms - pathology RNA, Messenger - analysis Urology |
| Title | Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0302283814012214 https://www.clinicalkey.es/playcontent/1-s2.0-S0302283814012214 https://dx.doi.org/10.1016/j.eururo.2014.11.038 https://www.ncbi.nlm.nih.gov/pubmed/25481455 https://www.proquest.com/docview/1751990561 |
| Volume | 69 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ra9swEBahg9GX0W1tl24rN9irG8eSY3tvwaxkKwmFrKVvQpbPkBKc4sQPhdLfvjtbTjfW0rJH2zpk-06n76S7T0J8RZpFitCSBqzKPZVJ30sSLLwstyryTWww5-Lk6Ww0uVA_r8Krnki7WhhOq3S-v_Xpjbd2dwbubw5uFovBnMyTuVuYsmkYBM1h1kpFbOUn9w9pHtIR78qmDFnGXflck-OFdVVXXAI4VCfM5clVKo9PT0_Bz2YaOt0Tbxx-hHH7im9FD8t34vXU7ZC_F3fn1Ypz5-gxXJpljbAqgEAepLhcQnpLQsBN2vTXEuZMYwmLEs5bgtU18MosN2lKjSBlq6i-wRjmW85naDcUwJQ5THFjPOOYTfbFxen3X-nEcycseDb05cYzzLiFWMgci6GPsQoC30QECa2f84GDsUmSrBhZZWOJZHMjjLOE4DihmFzmBHUOxE65KvGDgCxUkUko_DCmUKEfmMKQM2F2Nop3Q2v7QnY_VltHP86nYCx1l2d2rVt1aFYHRSaa1NEX3lbqpqXfeKZ92OlMd6Wl5Aw1zQ_PyEWPyeHajei1Hup1oH39j9X9KfmX4b6gzy-dUWka07xRY0pc1dRXRLg64diuLw5ba9t-PQX0MZPLH_13vx_FLl25daRPYmdT1fiZkNUmO26GzrF4Nf5xNpn9BmP6I2w |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED5KCttexrqf2drtBnv14lh2YvctmJV0bUIh7eibkOUzpASnOPHDoH9872w5bKyjY6-2Dtm60-k76e4TwBfiVaSILGvAhrkXZsr3koQKL8ttOPZNbCiX4uTZfDS9Cr9fR9d7kHa1MJJW6Xx_69Mbb-2eDNxoDm6Xy8GCzVO4W4SyaRgEcpn1vrBTRT3Yn5yeTec7h6wc965qKpFV3FXQNWleVFd1JVWAw_Cr0HlKocrDK9TfEGizEp28gOcOQuKk_coD2KPyJTyZuUPyV3B3Ua0lfY5f4w-zqgnXBTLOw5RWK0x_shBKkzYDtsSFMFnissSLlmN1g7I5K02aaiNMxTCqY5zgYkf7jO2ZApoyxxltjWccuclruDr5dplOPXfJgmcjX209I6RbRIXKqRj6FIdB4Jsxo0Lr53LnYGySJCtGNrSxIja7EcVZwoicgUyuckY7b6BXrkt6B5jx6JuEIxBjijDyA1MY9idC0MYhb2RtH1Q3sNo6BnK5CGOlu1SzG92qQ4s6ODjRrI4-eDup25aB45H2Uacz3VWXsj_UvEQ8Ijd-SI42blJv9FBvAu3rPwzvV8nfbPcf-vzcGZXmaS1nNaakdc19jRlaJxLe9eFta227v-eYPhZ--ff_3e8neDq9nJ3r89P52Qd4xm_cttIh9LZVTUcMtLbZRzeR7gFLbCYd |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Value+of+the+Cell+Cycle+Progression+Score+in+Patients+with+Prostate+Cancer%3A+A+Systematic+Review+and+Meta-analysis&rft.jtitle=European+urology&rft.au=Sommariva%2C+Silvia&rft.au=Tarricone%2C+Rosanna&rft.au=Lazzeri%2C+Massimo&rft.au=Ricciardi%2C+Walter&rft.date=2016-01-01&rft.issn=0302-2838&rft.volume=69&rft.issue=1&rft.spage=107&rft.epage=115&rft_id=info:doi/10.1016%2Fj.eururo.2014.11.038&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_eururo_2014_11_038 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03022838%2FS0302283815X00108%2Fcov150h.gif |